Site Map
Pages
- Mpox insights and intelligence
- Careers
- Our Story
- Academic Research
- Awards
- Customer Stories
- Home
- Risk Analysis Toolkit
- Predictive Intelligence
- Horizon Scanning and Risk Assessments
- Your Kinsa Alternative
- Newsroom
- Disease Prevention & Control Summit meeting request
- On-Demand Webinar: Omicron
- On Demand Webinar - MPOX Update Briefing #2
- On-Demand Webinar: MPOX
- Infographic: The return of travel and in-person gatherings
- Intelligence Report: 2021 Year In Review
- Intelligence Report Consultation Request
- Webinar: LLMs and Infectious Disease Intelligence
- Influenza-like-illnesses Trend Report
- ILI Pulse - Air Pollutants and their Impact on Severity
- ILI Consultation Request
- Request a demo
- BlueDot Newsletters
- Vaccines Summit 2023 - Boston MA
- World Vaccine Congress 2024 - Washington DC
- Download Influenza-like iIlness Trends Report
- Privacy Policy
- Contact Us
- Our People
- Enterprise
- Pharma
- Public Health
- Reports, Whitepapers & e-Books
- Talks & Panels
- Blog
Posts
- Whooping cough makes a sweeping global resurgence
- Zika: The public health risk hiding in plain sight
- In India, an elusive virus makes a devastating return
- What’s Next for Bird Flu: Q&A with BlueDot’s Experts
- Mpox: A Public Health Emergency Seeking a Global Response
- How this Fall’s Respiratory Infections Heighten Enterprise Risk
- Vaccines on the table as chikungunya outbreak intensifies in India
- Vaccine trial offers hope amid increasing Marburg virus outbreaks
- Did you know that polio is still a Public Health Emergency of International Concern?
- Lassa fever: The looming global health threat that remains overlooked
- How floods increase infectious disease risk
- How a global manufacturer stays at the forefront of consumer confidence
- How ASEAN BVC leverages BlueDot for disease intelligence
- Why Canada’s flag carrier benefits from BlueDot
- BlueDot is using AI to get ahead of the next pandemic
- Upwardly mobile: Six of Canada’s Top Growing Companies on how they keep on expanding
- LLMs take centre stage in the fight against infectious diseases
- Forecasting flu, RSV and COVID-19 severity this winter
- Good news moves fast for these tech companies
- How large language models can help prevent the next pandemic
- Navigating malaria control
- Infectious disease, an overlooked climate change impact: How leaders can help
- Your World Tonight - H5N1 and Canada
- Strategies on emerging pathogens for infection preventions
- Could AI help predict the next pandemic?
- An outbreak of the deadly Marburg virus has been confirmed. Here's what you need to know
- Relevance and impact: Connecting with HCPs in the digital age
- AI is already tracking the next pandemic
- U.S. reports 1st ‘domestically acquired’ malaria cases in 20 years
- Getting granular when tracking virus trends
- Only three Ebola-infected travellers per month are likely to fly from west Africa
- 11 CANADIAN TECH COMPANIES TO WATCH IN 2021
- 15 companies that are saving the world from COVID-19
- The computer algorithm that was among the first to detect the coronavirus outbreak
- How A.I.is aiding the coronavirus fight
- How AI spotted and tracked the coronavirus outbreak
- How Digital Health Technology Can Help Manage The Coronavirus Outbreak
- 2022–2023 global influenza activity analysis and commentary
- Revealing the Hidden Threat: Three innovative strategies for assessing disease burden today, tomorrow, and beyond
- Global influenza trends & future outlook report
- An OSINT approach to event-based surveillance for epidemic intelligence
- Mass gathering risk assessment framework
- How to build a resilient supply chain in the face of ongoing biothreats
- The AI revolution in pharma
- How AI-powered biothreat intelligence improves pharma sales & supply chain performance
- 5 top biothreat risks to enterprises in 2022
- BlueDot rapid risk assessment: Measles in Indonesia and the Philippines
- BlueDot rapid risk assessment: Travel health risks in Uganda
- Collision 2023 – BlueDot's Growth Summit Presentation
- Colliding Forces – The impact of climate change on infectious disease...
- Navigating the season ahead: influenza, RSV, and COVID-19 trends & impact
- Combatting mosquito-borne diseases with AI: Innovations in global health intelligence
- Unlocking the potential of wastewater data in infectious disease surveillance
- 2024 Respiratory trends: Navigating the threat of RSV, influenza, and COVID-19
- Live info session: New releases & impacts to your workflows
- BlueDot's 2024 Watchlist: The top 5 infectious disease threats you can't ignore
- Getting ahead of avian influenza: Why organizations need to prepare today
- Uncovering mpox: The underestimated crisis and its international spread
- Rising Uncertainty: Confronting the Impacts of ILIs and H5N1 in the U.S.
- Emerging pathogen threats: Strategies for infection prevention & control
- How preparedness is evolving in the GCC region: Strengthening resilience to emerging infectious disease threats
- Collision 2023 - Fireside Talk with Lauren Pelley and BlueDot's CEO
- How BlueDot is revolutionizing the fight against infectious diseases
- Bay Street Bull - How can we use artificial intelligence to disrupt infectious diseases?
- How innovation can help us outpace the next outbreak
- The Walrus Talks – Disease and disruption
- Why Medical Affairs needs to think about infectious diseases differently
- TEDx – Getting out of this pandemic and staying out of the next one
- Why AI is the missing piece in burden of disease calculations
- MaRS Discovery District - Cracking COVID-19: how BlueDot spots warning signs of pandemics
- The rise of vaccine-preventable diseases: spotlight on polio
- Innovation showcase: long-Term Dengue Forecasting
- Understanding and reducing the risks of viruses in shared spaces
- Fall 2022 respiratory disease trends & forecasts
- Monkeypox (Mpox) briefing
- How BlueDot is using LLMs to detect outbreaks faster
- All the Buzz on Mosquito-borne Diseases
- The Wastewater Whisperers
- Respiratory disease trends: 2024 and beyond
- Bird flu and beyond: The top 5 infectious diseases to look out for now
- Why organizations should start preparing for bird flu now
- Oropouche - a little-known virus becomes a sudden cause for concern
- Olympics 2024: Preventing infectious disease outbreaks during mass gatherings
- Transforming Public Health Surveillance
- BlueDot rapid risk assessment: South Africa’s cholera outbreak
- Unmasking COVID-19’s impact
- Outsmarting influenza-like-illnesses with intelligence
- BlueDot Now Available on Microsoft AppSource
- It’s been 20 years since SARS, what have we learned?
- Climate change likely to turn New York into a breeding ground for dengue-carrying mosquitoes
- When cases aren’t counted – why measuring burden of disease matters
- Government of Canada invests $3 million in BlueDot to expand its AI-powered disease surveillance and forecasting platform
- This World Cup is different – what we’ve learned about promoting healthier mass gatherings
- 5 Top Biothreat Risks to Enterprises in 2022
- AI-Powered Infectious Disease Intelligence in Pharmaceutical Organizations
- An OSINT Approach to Event Based Surveillance
- ILI Pulse: What do we know about emerging SARS-CoV-2 variants and global COVID-19 activity?
- ILI Pulse: A(H5N1) outbreaks in the USA
- Assessing Risk from Mass Gatherings
- Global Influenza Trends: 2021-2022 Season
- Summer 2022: Unexpected Disease Activity
- Monkeypox declared a global public health emergency – what’s next?
- Influenza spillover events on the rise
- Global influenza activity: the trends, changes, and predictions you need to know
- How we’re predicting stable reopenings
- COVID-19 in Sub-Saharan Africa
- UN recognizes BlueDot’s potential to transform tourism
- The latest on COVID-19 vaccines
- How predicting your airport choice helps us fight disease outbreaks
- The state of dengue during the COVID-19 pandemic
- An update on COVID-19 vaccine administration and candidates in Phase 3 clinical trials
- The state of COVID-19 in Mexico
- The COVID-19 strategies that stand out
- Assessing the COVID-19 vaccine candidates
- Update on COVID-19 in the Caribbean
- What Australia tells us about influenza and COVID-19
- On being named one of the Best Places to Work in Ontario
- How BlueDot’s technology is powering healthy airports
- Digital Health Company BlueDot Secures $7M USD Series A Financing
- How Worldwide Connectivity Is Fuelling the Measles Comeback
- Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel
- Anticipating the international spread of Zika virus from Brazil
- Modelling airport catchment areas to anticipate the spread of infectious diseases across land and air travel
- Inferring the true number of SARS-CoV-2 infections in Japan
- Potential for Mpox exportation from West and Central Africa through global travel networks
- Emergence and spread of SARS-CoV-2 lineage B.1.620 with variant of concern-like mutations and deletions
- Travel-related zika virus cases in Canada: October 2015 – June 2017
- Global expansion of SARS-CoV-2 variants of concern: dispersal patterns and influence of air travel
- Estimating the size of the monkeypox (Mpox) virus outbreak in Nigeria and implications for global control
- Potential for international spread of Oropouche virus via commercial air travel
- BlueDot places No. 25 on The Globe and Mail's fifth-annual ranking of Canada's Top Growing Companies
- BlueDot ranked number 15 on the list of Deloitte's Technology Fast 50™ program winners for 2023
- BlueDot signs Canada’s voluntary AI code of conduct
- BlueDot Awarded on the Financial Times Americas’ Fastest Growing Companies 2024 List
- BlueDot Awarded on Newsweek’s World’s Best Digital Health Companies
- BlueDot unveils next-gen global infectious disease surveillance solution, cutting manual detection time by nearly 90%
- BlueDot Strengthens Mpox Response with Advanced Surveillance Tools
- BlueDot further innovates in respiratory surveillance for the 2024 ILI season
- BlueDot partners with Japan to revolutionize global infectious disease surveillance with innovative early warning system
- Predictive analysis demonstrates a combined threat of flu, RSV, and COVID-19 this winter
- BlueDot pioneers new future of infectious disease intelligence with launch of the Global Disease Surveillance 3.0 engine
- Health Matrix expands its public health portfolio in the Middle East with BlueDot
- BlueDot’s latest offering empowers pharma and life science organizations to stay ahead of influenza and COVID disruptions
- BlueDot becomes Microsoft Partner to provide Enterprise organizations with actionable infectious disease intelligence, powered by AI
- Unprecedented and Unpredictable: What Businesses Can Learn From the 2022-23 Flu Season
- Government of Canada invests over $14 million to create jobs and grow economy across Greater Toronto Area
- BlueDot and Clarivate partner to strengthen the resilience of organizations, through heightened disease intelligence
- Combined impact of flu and COVID-19 expected to continue to plague U.S. businesses this winter
- BlueDot announces new leadership as it prepares for rapid growth in 2023
- BlueDot and ParticleOne help businesses and governments better protect people and mitigate disruption
- BlueDot, Inc. and Huron Join Forces to Strengthen an Organization’s Response to Epidemics
- Digital Health Company BlueDot Secures $7M USD Series A Financing
- Digital Health Company BlueDot Collaborates with Air Canada to Safeguard Customers and Employees from Infectious Diseases
- An AI epidemiologist sent the first warnings of the Wuhan virus
- How this Canadian start-up spotted coronavirus before everyone else knew about it
- Toronto doctor develops algorithm to track infectious diseases and predict outbreaks
- From chaos to coherence: managing pandemics with data
- Travel precautions persist for Zika-hit areas
- How a Toronto company used big data to predict the spread of Zika
- Case Study: City of Chicago
- Case Study: Taiwan Center for Disease Control